AACR 2023 – Moderna's immunotherapeutic splash

Big pharma watchers and biotech investors alike will be looking forward to next month’s instalment of AACR. The meeting, normally a haven of early preclinical research, will in 2023 feature several prominent clinical results, the biggest of which might concern Moderna’s immunotherapeutic mRNA-4157, which attracted a $250m opt-in from Merck & Co last October.